In the wake of the FDA being forced to release massive amounts of data on Pfizer's mRNA COVID shot clinical trials, the drug company has revised its fourth quarter investors report to reflect concerns about that data.
Quite noticeably, Pfizer's now tempering their previously glowing predictions of $54 billion in sales in 2022 with new disclosures of unfavorable safety data that may come to light under audits or inspections. As noted by Twitter posts and ZeroHedge, some of the notations are buried "deep in its business risk disclosures."
At the same time, Pfizer is also acknowledging to investors that the pandemic may "diminish in severity or prevalence, or disappear entirely."
SOURCE: ZeroHedge February 9, 2022